Abstract
Background Particulate matter and volatile organic compounds, including total hydrocarbons (THCs), are major ambient air pollutants. The primary nonmethane hydrocarbons (NMHCs) originate from vehicle emissions. Studies on the association between air pollution and urinary bladder cancer (UBC) have revealed contradictory results.
Objectives The present study investigated whether long-term exposure to ambient hydrocarbons increases UBC risk among people aged ≥20 years in Taiwan.
Methods Linkage dataset research with longitudinal design was conducted on 600,666 cancer-free individuals from 2000–2013; 12 airborne pollutants were determined. Several Cox models considering potential confounders were employed. The study outcomes were invasive or in situ UBC incidence over time. The targeted pollutant concentration was divided into three tertiles: T1/T2/T3.
Results The mean age of the individuals at risk was 42.8 (SD, 15.7), and 50.2% were men. The mean daily average over 10-years of airborne THC concentration was 2.24 ppm (SD, 0.14), and NMHC was 0.29 ppm (SD, 0.09). There was a dose-dependent increase in UBC at follow-up. The incidence of UBC cases per 100,000 people by T1/T2/T3 exposure to THC was 60.3, 203.7, and 450.8, respectively; it was 180.2/202.4/453.8 per 100,000, corresponding to T1/T2/T3 exposure to NMHC, respectively. Without controlling for confounding air pollutants, the adjusted hazard ratio (adj.HR) was 1.77 (95% CI, 1.69–1.87) per 0.14 ppm increase of THC; after controlling for PM2.5, adj.HR was even higher at 2.10 (95% CI, 1.99– 2.22). The adj.HR was 1.38 (95% CI, 1.31–1.44) per 0.09 ppm increase in ambient NMHC concentration. After controlling for SO2 and CH4, the adj.HR was 1.16 (95% CI, 1.11–1.21). Sensitivity analyses showed that the UBC development risk was not sex-specific or influenced by diabetes status.
Discussion Long-term exposure to THC and NMHC may be a risk factor for UBC development. Acknowledging the pollutant sources can inform risk management strategies.
Competing Interest Statement
Han-Wei Zhang, Hsiao-Ching Peng reports equipment and statistical analysis were provided by Biomedica Corporation. Han-Wei Zhang reports a relationship with Biomedica Corporation that includes: board membership. Hsiao-Ching Peng reports a relationship with Biomedica Corporation that includes: employment. Both received support for using the product Meta Trial Software to conduct the present research. Both declare that they had full access to all the data in this study and take complete responsibility for the integrity of the data and the accuracy of the data analysis. The other authors declare that they have no competing interests.
Funding Statement
This research was partially supported by the Ministry of Science and Technology through the Center for Precision Medicine Research of Asia University in Taiwan (grant number: MOST 110-2321-B-468-001).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved after a full ethical review by the Institutional Review Board (IRB) of the China Medical University, Taichung, Taiwan (approval number: CMUH104-REC2-115 [CR-6]). In addition, because de-identified/anonymized data were used from the NHIRD, the IRB waived the requirement to obtain informed consent from the study participants. All experiments were performed according to confidentiality guidelines set forth by the Taiwan Personal Information Protection Act regulations. The entire study was conducted in accordance with the Declaration of Helsinki.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* These two authors share first authorship.
omnizhang{at}biomdcare.com
jainepeng{at}biomdcare.com
ren{at}asia.edu.tw
jjptsai{at}gmail.com
vkok{at}alumni.harvard.edu.
yauhung{at}mail.tku.edu.tw.
hsuc{at}mail.cmu.edu.tw
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
List of abbreviations
- AhR
- aryl hydrocarbon receptor
- CI
- confidence interval
- EPA
- Environmental Protection Administration
- HR
- hazard ratio
- IDC-9-CM
- International Classification of Disease, Ninth Revision, Clinical Modification
- NHIRD
- National Health Insurance Research Database
- NMHC
- nonmethane hydrocarbon
- OR
- odds ratio
- PAHs
- polycyclic aromatic hydrocarbons
- PM
- particulate matter
- RR
- relative risk
- T
- tertile
- THC
- total hydrocarbon
- UBC
- urinary bladder cancer
- VOCs
- volatile organic compounds